
SPARK Neuro is a pioneering neuroscience company focused on transforming dementia assessment through its innovative SPARK Scan, an FDA-cleared, Class-II device that utilizes EEG and AI for accurate, non-invasive neurological analysis. The company aims to address the significant issue of undiagnosed dementia, which affects millions, by providing a solution that reduces false positives and enhances early diagnosis, ultimately improving patient outcomes and reducing healthcare costs. With a mission to make brain health measurement universal and accessible, SPARK Neuro is positioned at the forefront of brain health technology, backed by a team of experts and significant funding.

SPARK Neuro is a pioneering neuroscience company focused on transforming dementia assessment through its innovative SPARK Scan, an FDA-cleared, Class-II device that utilizes EEG and AI for accurate, non-invasive neurological analysis. The company aims to address the significant issue of undiagnosed dementia, which affects millions, by providing a solution that reduces false positives and enhances early diagnosis, ultimately improving patient outcomes and reducing healthcare costs. With a mission to make brain health measurement universal and accessible, SPARK Neuro is positioned at the forefront of brain health technology, backed by a team of experts and significant funding.
Product: SPARK Scan — ~10-minute EEG + ML dementia assessment (FDA-cleared, Class II)
Founded: 2017
Headquarters: New York, NY
Stage / Funding: Reported total funding $23.5M; notable Series A $13.5M (2018)
Founder / CEO: Spencer Gerrol
Undiagnosed and late-diagnosed dementia; brain health measurement for clinical care and therapeutic discovery.
2017
Biotechnology
13500000
Reported participants included Will Smith and Michael Eisner.
Last funding date listed in company snapshot; details not specified in evidence.
“Alchimia Investments, AngelList, Connectivity Ventures Fund, King River Capital, KittyHawk, MBX Capital, Michael Eisner, Proton Enterprises, R136 Ventures, Thiel Capital, Trajectory Ventures, Will Smith”